PMID- 29753737
OWN - NLM
STAT- MEDLINE
DCOM- 20181022
LR  - 20181022
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 501
IP  - 2
DP  - 2018 Jun 22
TI  - miR-196b is a prognostic factor of human laryngeal squamous cell carcinoma and 
      promotes tumor progression by targeting SOCS2.
PG  - 584-592
LID - S0006-291X(18)31101-X [pii]
LID - 10.1016/j.bbrc.2018.05.052 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) has the second highest 
      incidence among the head and neck malignancies. Additionally, the incidence of 
      LSCCs has been recently increasing. Therefore, understanding the mechanisms of 
      LSCC tumorigenesis and identifying novel biomarkers to accurately predict and 
      improve the prognosis of patients with LSCC is extremely important. METHODS: 
      miR-196b and SOCS2 expression was measured by qRT-PCR and western blot. Their 
      correlation was analyzed with the Pearson test. TU212 and TU177 cells were 
      cultured and transfected for MTT, Transwell, and apoptosis assays upon miR-196b 
      knockdown, SOSC2 overexpression or SOCS2 silencing. Dual-luciferase reporter 
      assay were conducted to identify the relationship between miR-196b and SOCS2. 
      Moreover, the correlation between clinicopathological parameters and 
      miR-196b/SOCS2 expression in patients was analyzed. Univariate and multivariate 
      analysis and log-rank tests were used to determine if miR-196 was an independent 
      LSCC prognostic factors. RESULTS: We reported the aberrant expression and inverse 
      correlation of miR-196b and SOCS2 in LSCC samples. miR-196b promoted LSCC cells 
      proliferation and invasion, and suppressed apoptosis by directly inhibiting SOCS2 
      expression in vitro. Moreover, we also revealed that miR-196b/SOCS2 expression 
      correlated with T stage and cervical metastasis. miR-196b was demonstrated to be 
      an independent prognostic factor for overall survival of patients with LSCC. 
      CONCLUSIONS: Overexpression of miR-196b suppresses SOCS2 in human LSCC resulting 
      in tumor progression and poor prognosis. miR-196b is a potential marker for 
      prognosis assessment and targeting miR-196b may be a novel valuable strategy for 
      the treatment of LSCC.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Zhao, Xudong
AU  - Zhao X
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Endocrinology Shengjing Hospital, China Medical University, 
      Shenyang, China.
FAU - Ji, Wenyue
AU  - Ji W
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang, China. Electronic address: jiwenyueent@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (MIRN196 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (SOCS2 protein, human)
RN  - 0 (Suppressor of Cytokine Signaling Proteins)
SB  - IM
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics/pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/diagnosis/*genetics/pathology
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Prognosis
MH  - Suppressor of Cytokine Signaling Proteins/*genetics
MH  - Up-Regulation
OTO - NOTNLM
OT  - LSCC
OT  - Laryngeal cancer
OT  - SOCS2
OT  - miR-196b
EDAT- 2018/05/14 06:00
MHDA- 2018/10/23 06:00
CRDT- 2018/05/14 06:00
PHST- 2018/04/30 00:00 [received]
PHST- 2018/05/09 00:00 [accepted]
PHST- 2018/05/14 06:00 [pubmed]
PHST- 2018/10/23 06:00 [medline]
PHST- 2018/05/14 06:00 [entrez]
AID - S0006-291X(18)31101-X [pii]
AID - 10.1016/j.bbrc.2018.05.052 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2018 Jun 22;501(2):584-592. doi: 
      10.1016/j.bbrc.2018.05.052.